According to a new report published this month (Global Antibody Drug Conjugate Market Outlook 2018) the ADC market is anticipated to reach US$ 3.45 Billion by 2018.
A review of the best selling monoclonal antibodies in 2013 and 2012 is provided. Humira with sales of over $11 billion ($9.3 billion in 2012) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2013 as in 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012 Table. Remicade (9.7 Bn), Rituxan (7.5 Bn) , Herceptin (6.5 Bn) and Avastin (6.5 Bn) were the second, third, fourth and fifth top selling mabs in 2013. The actual sales for 2013 as reported by the companies are provided. The total sales of the top selling blockbuster mabs were $63 billion in 2013. The actual global sales of all the approved blockbuster sales or potential (sales >1 billion) monoclonal antibodies in 2013 is provided. Besides the top 5 mabs, there were 2 other monoclonal antibodies with sales of over 2 billion dollars and 5 with sales of over $ 1 billion in 2013. In addition 5 recently launched mabs were nearing to reach sales of $ 1 billion this year. Currently 30 monoclonal antibodies are marketed in the US and Europe (January 2014). Alexion Soliris was the most expansive marketed monoclonal antibody with a price tag of $440,000 per year of treatment, a sort of Rolls-Royce of mabs.
Roche is at the forefront in developing antibody-drug conjugates (ADCs) that combine the specificity of antibodies with the power of chemotherapy. This video... (RT @Roche: Roche is at the forefront in developing antibody-drug conjugates.
Key Points. SGN-CD33A is a novel antibody-drug conjugate, consisting of an engineered anti-CD33 mAb conjugated to a potent DNA cross-linking cytotoxin. SGN-CD33A is highly active in a broad panel of preclinical AML ...
Lonza to Expand Antibody Drug Conjugate (ADC) Manufacturing Capacity to Meet Growing Customer Demand (RT @LonzaGroup: Lonza to Expand Antibody Drug Conjugate (ADC) Manufacturing Capacity to Meet Growing Customer Demand -
Intellect Neurosciences and iNovacia Enter Research Service Agreement to ...NASDAQWe believe the antibody drug conjugate will show improved efficacy compared to the naked amyloid beta antibodies currently in clinical development for AMD.
CAMBRIDGE, Mass. July 31, 2012 - Mersana Therapeutics, Inc., a biopharmaceutical company developing its Fleximer® antibody-drug conjugate platform and (Mersana Therapeutics, Inc.
The Biological SCENE Building Better Therapeutic Antibodies The Biological SCENE To make an antibody-drug conjugate, researchers added galactose (purple circles) and sialic acid (blue triangles) to carbohydrate chains (open shapes) on a...
Genmab, ADC partner to develop new antibody-drug conjugate to treat cancer Pharmaceutical Business Review The collaboration will integrate Genmab's high-affinity fully human antibody targeting CD25, HuMax-TAC, with ADC's PBD-based warhead and...
Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High Marketwire (press release) Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer,...
Pharmaceutical Industry | NEWS | General | Abbott and Seattle expand antibody-drug conjugate collaboration - Pharma company could pay $220m per oncology target | PMLiVE (#oncology Abbott and Seattle expand antibody-drug conjugate collaboration
In the run up to World ADC (23 - 25 October 2012, San Francisco), I'd like to share with you a presentation delivered by Chantal Zuber, Manager, Research Immunology, Biotest.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Your new post is loading...
Scoop.it!
